Zai Lab Ltd (NASDAQ:ZLAB) — Market Cap & Net Worth
Market Cap & Net Worth: Zai Lab Ltd (ZLAB)
Zai Lab Ltd (NASDAQ:ZLAB) has a market capitalization of $2.24 Billion ($2.24 Billion) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5849 globally and #1783 in its home market, demonstrating a -1.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zai Lab Ltd's stock price $21.54 by its total outstanding shares 112069482 (112.07 Million). Analyse Zai Lab Ltd cash flow conversion to see how efficiently the company converts income to cash.
Zai Lab Ltd Market Cap History: 2017 to 2026
Zai Lab Ltd's market capitalization history from 2017 to 2026. Data shows change from $2.38 Billion to $2.41 Billion (-2.97% CAGR).
Index Memberships
Zai Lab Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.09% | #141 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #628 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.13% | #89 of 263 |
Weight: Zai Lab Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zai Lab Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zai Lab Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.36x
Zai Lab Ltd's market cap is 7.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.60 Billion | $129.45K | -$139.07 Million | 20102.07x | N/A |
| 2019 | $4.66 Billion | $12.98 Million | -$183.37 Million | 358.96x | N/A |
| 2020 | $15.17 Billion | $48.96 Million | -$268.90 Million | 309.81x | N/A |
| 2021 | $7.04 Billion | $144.31 Million | -$704.47 Million | 48.81x | N/A |
| 2022 | $3.44 Billion | $215.04 Million | -$443.29 Million | 16.00x | N/A |
| 2023 | $3.06 Billion | $266.72 Million | -$334.62 Million | 11.48x | N/A |
| 2024 | $2.94 Billion | $398.99 Million | -$257.10 Million | 7.36x | N/A |
Competitor Companies of ZLAB by Market Capitalization
Companies near Zai Lab Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Zai Lab Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Zai Lab Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Zai Lab Ltd's market cap moved from $2.38 Billion to $ 2.41 Billion, with a yearly change of -2.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.41 Billion | +22.11% |
| 2025 | $1.98 Billion | -32.65% |
| 2024 | $2.94 Billion | -4.17% |
| 2023 | $3.06 Billion | -10.98% |
| 2022 | $3.44 Billion | -51.15% |
| 2021 | $7.04 Billion | -53.56% |
| 2020 | $15.17 Billion | +225.41% |
| 2019 | $4.66 Billion | +79.11% |
| 2018 | $2.60 Billion | +9.37% |
| 2017 | $2.38 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zai Lab Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.24 Billion USD |
| MoneyControl | $2.24 Billion USD |
| MarketWatch | $2.24 Billion USD |
| marketcap.company | $2.24 Billion USD |
| Reuters | $2.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more